4-Chloro-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
98%
- Product Code: 164954
CAS:
244057-36-1
| Molecular Weight: | 292.67 g./mol | Molecular Formula: | C₁₃H₉ClN₂O₄ |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD30188071 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8°C, drying away from light |
Product Description:
Used primarily as a key intermediate in the synthesis of immunomodulatory drugs, particularly in the production of lenalidomide and related compounds. It plays a critical role in targeted protein degradation therapies, especially in oncology. The compound functions as a precursor to cereblon E3 ligase modulators, which are employed in the treatment of multiple myeloma, myelodysplastic syndromes, and other hematological cancers. Its structure enables selective binding to cereblon, leading to the degradation of disease-causing proteins. Widely utilized in pharmaceutical research and development for designing novel proteolysis-targeting chimeras (PROTACs) and other degradation-based therapeutics.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | Gray solid |
| Purity (%) | 97.5-100% |
| Infrared Spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 100mg | 10-20 days | €10.78 |
+
-
|
| 250mg | 10-20 days | €21.30 |
+
-
|
| 1g | 10-20 days | €51.29 |
+
-
|
| 5g | 10-20 days | €174.91 |
+
-
|
| 25g | 10-20 days | €617.83 |
+
-
|
| bulk | 10-20 days | €0.00 |
+
-
|
4-Chloro-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
Used primarily as a key intermediate in the synthesis of immunomodulatory drugs, particularly in the production of lenalidomide and related compounds. It plays a critical role in targeted protein degradation therapies, especially in oncology. The compound functions as a precursor to cereblon E3 ligase modulators, which are employed in the treatment of multiple myeloma, myelodysplastic syndromes, and other hematological cancers. Its structure enables selective binding to cereblon, leading to the degradation of disease-causing proteins. Widely utilized in pharmaceutical research and development for designing novel proteolysis-targeting chimeras (PROTACs) and other degradation-based therapeutics.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
€0.00
€0.00
Total :